# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst Daniel Grosslight maintains McKesson (NYSE:MCK) with a Buy and lowers the price target from $670 to $630.
Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Geron...
Leerink Partners analyst Michael Cherny maintains McKesson (NYSE:MCK) with a Outperform and lowers the price target from $67...
- SEC Filing
McKesson Canada will continue to own and operate Rexall and Well.ca until transaction close, which is subject to customary clos...
Three major U.S. drug distributors, McKesson, Cencora, and Cardinal Health, have agreed to a $300 million settlement over claim...